Remove Cosmetics Remove Regulation Remove Research
article thumbnail

TN DCA issues circular asking pharmacists in medical shops to wear white coat and badges

AuroBlog - Aurous Healthcare Clinical Trials blog

Although provisions of the Pharmacy Practice Regulations (PPR) 2015 are not there in the Drugs and Cosmetics (D&C) Act 1940 but are framed under the Pharmacy Act 1948, the steps now being taken by the drugs control administration (DCA) in Tamil Nadu in a motive to strengthen the dispensing activities in pharmacies are completely agreeing […] (..)

Cosmetics 189
article thumbnail

D&C Rules need revamp as there is no clause of compensation for ADRs: regulatory experts

AuroBlog - Aurous Healthcare Clinical Trials blog

Taking into account the four main components of regulator, industry, trade and patient/consumer in a medicine value supply chain, the Drugs and Cosmetics (D&C) Rules, 1945 and D&C Act, 1940 needs an urgent revamp as there is no clause of compensation for ADRs in patients, according to drug regulatory experts.

Cosmetics 189
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

CBD Research: A Dive into the Regulations of Cannabis Research

Advarra

As such, we are seeing an uptick in research examining the therapeutic effects of cannabis and its constituents. While there isn’t a significant amount of research on cannabidiol (CBD), it’s easily accessible in the U.S. This can make research challenging, but not insurmountable. Funding Research on Cannabis.

article thumbnail

The Art and Science of Panelist Recruitment for Cosmetics Clinical Studies

Cloudbyz

In the cosmetics industry, innovation is key to staying ahead of the competition. As consumer preferences evolve and regulatory demands increase, cosmetics companies are under pressure to prove the safety and efficacy of their products through rigorous clinical studies.

article thumbnail

Biologic Therapeutics Development, Part 2: Regulatory Pathways and Pharmacometric Analysis

Camargo

Both the FDA’s Center for Drug Evaluation and Research (CDER) and its Center for Biologics Evaluation and Research (CBER) have regulatory responsibility for therapeutic biological products, which are subject to both the Federal Food, Drug and Cosmetic (FD & C) Act and the Public Health Service (PHS) Act. BLA process (CBER).

article thumbnail

FDA Designations for Rare Disease Products, Part 1

Camargo

Where is the regulation found? 21 Code of Federal Regulations (CFR) §316 ; Orphan Drug Act. Section 529 of the Federal Food, Drug, and Cosmetic Act (FD&C Act)/ 21 United States Code (USC) §360ff. Potential Pediatric Research Equity Act (PREA) requirements exemption. Orphan Drug Designation. 21 CFR §814 Subpart H.

article thumbnail

ACI To Host Multiple Events Featuring HP&M Speakers – Discounts Available to FDA Law Blog Readers

FDA Law Blog

The American Conference Institute (“ACI”) will be hosting a series of go-to forums on critical topics including novel therapeutics, cosmetics/personal care products and Paragraph IV disputes. Claud will be featured at the Legal, Regulatory, and Compliance Forum on Cosmetics & Personal Care Products in New York, NY.